SpliceBio Webinar: Pioneering a Novel Gene Therapy for Stargardt Disease
Tune in to learn more about a promising new gene therapy for Stargardt disease, currently being developed by SpliceBio.
SB-007 is designed to address the root cause of Stargardt disease and is now being evaluated in clinical trials. Whether you are living with Stargardt, supporting someone who is, or working in the field, this is a valuable opportunity to learn, engage, and ask questions directly to the SpliceBio team.
Event Details
Date: Thursday, October 2, 2025
Time: 12:00–1:00 PM ET
Location: Zoom (link provided upon registration)
Cost: Free
What to Expect
- Hear from SpliceBio representatives about the principles of gene therapy.
- Learn how SB-007 offers a novel approach to treatment.
- Get details on the ongoing clinical studies.
This webinar will be recorded and made available on our YouTube channel after the event. Make sure to subscribe to receive a notification when the recording is available! If you have any questions or need help registering, please email development@carroll.org or call (617) 969-6200 x 236.
About the speakers
John Tobin
John Tobin has worked in the pharmaceutical/biotechnology sector for 30 years. He has dedicated a large part of his career to conducting gene therapy, clinical development programmes in Geographic Atrophy as well as in the treatment of inherited retinal diseases such as Choroideremia, and X-linked Retinitis Pigmentosa. John heads up the Clinical Operations division at SpliceBio where his primary focus has been to bring the novel gene therapy, SB-007, to Stargardt subjects via the ASTRA Clinical Trial that commenced in early 2025.
Dr. Feride Sahin
Dr. Feride Sahin is a medical doctor who has worked in the pharmaceutical industry for more than 25 years, with the last 15 years dedicated to ophthalmology. Throughout her career, she has focused on medical affairs and clinical development across a range of ophthalmic indications. She is currently Senior Director of Clinical Development at SpliceBio, where her primary focus is advancing innovative therapies for patients with high unmet medical needs in ophthalmology.
